ReviewJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2013
Novel strategies for anterior segment ocular drug delivery.
Review in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Trial
- Meibomian Gland-Mediated Drug Delivery via Eyelid Application of Troxipide Nanoparticles Improves an N-Acetylcysteine-Induced Dry Eye.Pharmaceutics · 2026Article
- Nose-to-Eye Delivery: The Potential of Intranasal Administration in Ophthalmology.Journal of clinical medicine · 2026Review
- Ocular Troxipide Nanosuspension Enhances Therapeutic Efficacy in an N-Acetylcysteine-Induced Dry Eye Model.Pharmaceutics · 2026Article
- A Dual-Drug Nanocarrier Strategy for Ocular Fungal Infections: Micelles Embedded in Electrospun Nanofibers.Molecules (Basel, Switzerland) · 2026Article
- Emerging innovations in ophthalmic drug delivery for diabetic retinopathy: a translational perspective.Drug delivery and translational research · 2026Review
- Keratoconjunctivitis Sicca in Sjögren Disease: Diagnostic Challenges and Therapeutic Advances.International journal of molecular sciences · 2025Review
- Emerging trends in long-acting sustained drug delivery for glaucoma management.Drug delivery and translational research · 2025Review
- Modified diatom-based ocular suspension for sustained diclofenac sodium delivery: a novel drug carrier approach.BMC pharmacology & toxicology · 2025Article
- Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Overview of processed excipients in ocular drug delivery: Opportunities so far and bottlenecks.Heliyon · 2024Review
- Application of sphingolipid-based nanocarriers in drug delivery: an overview.Therapeutic delivery · 2024Review
- Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders.Current drug research reviews · 2024Review
- Light-responsive biomaterials for ocular drug delivery.Drug delivery and translational research · 2023Review
- Application of Hydrogels in the Device of Ophthalmic Iontophoresis: Theory, Developments and Perspectives.Gels (Basel, Switzerland) · 2023Review
- Advances in Nanogels for Topical Drug Delivery in Ocular Diseases.Gels (Basel, Switzerland) · 2023Review
- Topical Application of Linezolid-Loaded Chitosan Nanoparticles for the Treatment of Eye Infections.Nanomaterials (Basel, Switzerland) · 2023Article
- Antiviral role of nanomaterials: a material scientist's perspective.RSC advances · 2022Review
- Protein and polypeptide mediated delivery to the eye.Advanced drug delivery reviews · 2022Review
- Lactoferrin and its nano-formulations in rare eye diseases.Indian journal of ophthalmology · 2022Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Research advancements in pharmaceutical sciences have led to the development of new strategies in drug delivery to anterior segment. Designing a new delivery system that can efficiently target the diseased anterior ocular tissue, generate high drug levels, and maintain prolonged and effective concentrations with no or minimal side effects is the major focus of current research. Drug delivery by traditional method of administration via topical dosing is impeded by ocular static and dynamic barriers. Various products have been introduced into the market that prolong drug retention in the precorneal pocket and to improve bioavailability. However, there is a need of a delivery system that can provide controlled release to treat chronic ocular diseases with a reduced dosing frequency without causing any visual disturbances. This review provides an overview of anterior ocular barriers along with strategies to overcome these ocular barriers and deliver therapeutic agents to the affected anterior ocular tissue with a special emphasis on nanotechnology-based drug delivery approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.